1-19 of 19
Joanna Opalinska
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Meral Beksac, Esther Gonzalez Garcia, Sosana Delimpasi, Pawel Robak, Kamaraj Karunanithi, Felipe De Arriba, Jakub Radocha, Kihyun Kim, Sergey Voloshin, Vera Zherebtsova, Iurii Osipov, Maria-Victoria Mateos, Syed F. Zafar, Luděk Pour, Ivan Spicka, Kazuhito Suzuki, Xin Du, Jodie Wilkes, Brijesh Maroj, Kristin Morris, Jie Ma, Margaret Polinkovsky, Zhaohui Wang, Xiaoou L Zhou, Giulia Fulci, Neal Sule, Brandon Kremer, Joanna Opalinska, Suzanne Trudel, Meletios A. Dimopoulos
Journal: Blood
Blood (2024) 144 (Supplement 1): 4731.
https://doi.org/10.1182/blood-2024-199282
Published: 2024
Journal Articles

Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Vania Hungria, Marek Hus, Pawel Robak, Vera Zherebtsova, Ana Carolina de Almeida Ribas, Marcelo Pitombeira de Lacerda, Kihyun Kim, Sebastian Grosicki, Irwindeep Sandhu, Christopher Ward, Astrid McKeown, Hena Baig, Jie Ma, Benjamin Lariviere, Benga Kazeem, Lydia Eccersley, Sumita Roy-Ghanta, Joanna Opalinska, Maria Victoria Mateos
Journal: Blood
Blood (2024) 144 (Supplement 1): 3359.
https://doi.org/10.1182/blood-2024-201543
Published: 2024
Journal Articles

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Vania T.M Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gabor Mikala, Tamas Masszi, Jian Li, Marcelo Capra, Angelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Low, Morio Matsumoto, Mary Li, Neal Sule, Margaret Polinkovsky, Randy Davis, Shelley Bright, Astrid McKeown, Joanna Opalinska, Meletios Athanasios Dimopoulos
Journal: Blood
Blood (2023) 142 (Supplement 1): 3357.
https://doi.org/10.1182/blood-2023-178009
Published: 2023
Journal Articles

Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a

Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi Kasinathan, Rachel Rogers, Amy Curry, Fernando Carreno, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach
Journal: Blood
Blood (2023) 142 (Supplement 1): 2010.
https://doi.org/10.1182/blood-2023-178044
Published: 2023
Journal Articles

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Ajay K. Nooka, Adam Cohen, Hans C. Lee, Ashraf Z. Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward Libby, Maria Chaudhry, Malin Hultcrantz, Martin Kortuem, Paul G. Richardson, Rakesh Popat, Douglas W. Sborov, Shawn Hakim, Eric Lewis, Bharat Bhushan, Boris Gorsh, Ira Gupta, Joanna Opalinska, Sagar Lonial
Journal: Blood
Blood (2022) 140 (Supplement 1): 7301–7303.
https://doi.org/10.1182/blood-2022-164877
Published: 2022
Journal Articles

Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14

Malin Hultcrantz, David Kleinman, Pavandeep Ghataorhe, Astrid McKeown, Wei He, Thomas Ling, Roxanne C Jewell, Joseph Brunner, Julie Byrne, Laurie Eliason, Emma Scott, Joanna Opalinska
Journal: Blood
Blood (2021) 138 (Supplement 1): 1645.
https://doi.org/10.1182/blood-2021-152224
Published: 2021
Journal Articles

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sagar Lonial, MD FACP, Peter M. Voorhees, MD, Simona Degli Esposti, MD, Ira Gupta, MD, Joanna Opalinska, MD, Sandhya Sapra, PhD, Boris Gorsh, PharmD, Zangdong He, PhD, David M Kleinman, MD, Debra Schaumberg, OD, MPH, ScD, Angely Loubert, PharmD, MSc, Juliette Meunier, MSc, Antoine Regnault, PhD, Laurie Eliason, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-140013
Published: 2020
Journal Articles

Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Geraldine Ferron-Brady, PhD, Chetan Rathi, PhD, Jon Collins, PhD, Herbert Struemper, PhD, Joanna Opalinska, MD, Roxanne C Jewell, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139698
Published: 2020
Journal Articles

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Rakesh Popat, Aikaterini Kazantzi, MD, Asim Farooq, MD, Praneetha Thulasi, MD, Sagar Lonial, MD FACP, Andrzej Jakubowiak, MD PhD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Joanna Opalinska, MD, January Baron, MS, Trisha Piontek, BSN, Julie Byrne, PhD, Lynsey Womersley, MSc, Ira Gupta, MD, Simona Degli Esposti, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-139315
Published: 2020
Journal Articles

Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

Laurie Eliason, MPH, Julia Correll, MPH, Mona Martin, MPA, Anna Cardellino, MPH, Joanna Opalinska, MD, Trisha Piontek, BSN, Boris Gorsh, PharmD, Sandhya Sapra, PhD, Rakesh Popat
Journal: Blood
Blood (2020) 136 (Supplement 1): 1.
https://doi.org/10.1182/blood-2020-139395
Published: 2020
Journal Articles

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ajay Nooka, MDMPH, Hans C. Lee, MD, Ashraf Z. Badros, MD, Peter Voorhees, MD, Malin Hultcrantz, MD PhD, Lionel Karlin, MD, Bertrand Arnulf, MD, Paul G. Richardson, MD, Eric Zhi, PhD, January Baron, MS, Trisha Piontek, BSN, Eric Lewis, MD, Joanna Opalinska, MD PhD, Ira Gupta, MD, Adam D. Cohen, MD, Sagar Lonial, MD FACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-139687
Published: 2020
Journal Articles

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sagar Lonial, MD FACP, Ajay Nooka, MDMPH, Praneetha Thulasi, MD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Natalie S. Callander, MD, Douglas Sborov, MD MS, Brian E. Zaugg, MD, Rakesh Popat, Simona Degli Esposti, MD, Julie Byrne, PhD, Joanna Opalinska, MD PhD, January Baron, MS, Trisha Piontek, BSN, Ira Gupta, MD, Reza Dana, MD MSc, MPH, Asim Farooq, MD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140078
Published: 2020
Journal Articles

Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Katja Weisel, Thomas G Hopkins, Doug Fecteau, Weichao Bao, Corinne Quigley, Roxanne C Jewell, Maureen Nichols, Joanna Opalinska
Journal: Blood
Blood (2019) 134 (Supplement_1): 1900.
https://doi.org/10.1182/blood-2019-129893
Published: 2019
Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska
Journal: Blood
Blood (2019) 134 (Supplement_1): 1857.
https://doi.org/10.1182/blood-2019-129879
Published: 2019
Journal Articles

Expression of Myeloma Cell and Soluble B-Cell Maturation Antigen (BCMA) in Relapsed and Refractory Multiple Myeloma Patients Treated with GSK2857916 in BMA117159

E.J. Dettman, PhD BS, Fabio Rigat, PhD, Josh Albert, BS, Ruth Barnard, PhD, Mary Birchler, BS, Yan Deghenhardt, PhD, Stephen DeWall, PhD, Boyenoh Gaye, MS, Zangdong He, PhD, Veronica Liu, MS, Joanna Opalinska
Journal: Blood
Blood (2018) 132 (Supplement 1): 1977.
https://doi.org/10.1182/blood-2018-99-115200
Published: 2018
Journal Articles

Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

Jenny Willson, Amanda Bruno, Joanna Opalinska, Jeannene Nelson, Orsolya Lunacsek, Dana Stafkey-Mailey, Joanne Willey
Journal: Blood
Blood (2018) 132 (Supplement 1): 3290.
https://doi.org/10.1182/blood-2018-99-112954
Published: 2018
Journal Articles

A High Resolution Epigenomic Map of Myelofibrosis Reveals Multiple Chromosomal Deletions and Amplifications Accompanied by a High Level of Functionally Important Methylation.

Joanna Opalinska, Davendra Sohal, Simrit Parmar, Li Zhou, Andrew Yeatts, Perry Pahanish, Iris Isulfi, Kenny Ye, Maria Figueroa, Ari Melnick, John Greally, Amit Verma
Journal: Blood
Blood (2006) 108 (11): 2684.
https://doi.org/10.1182/blood.V108.11.2684.2684
Published: 2006
Journal Articles

High Resolution Epigenomic Mapping of Myelodysplastic Syndrome Reveals a High Level of Functionally Important Methylation.

Li Zhou, Joanna Opalinska, Davendra Sohal, Simrit Parmar, Perry Pahanish, Iris Isulfi, Kenny Ye, Maria Figueroa, John Greally, Ari Melnick, Amit Verma
Journal: Blood
Blood (2006) 108 (11): 2637.
https://doi.org/10.1182/blood.V108.11.2637.2637
Published: 2006
Journal Articles

Meta-Transcriptome of Bone Marrow Stem Cells Demonstrates Platform and Lab Dependant Variability in Gene Expression and Reveals a Novel Set of Enriched Genes.

Davendra Sohal, Andrew Yeatts, Joanna Opalinska, Li Zhou, Perry Pahanish, Kenny Ye, Maria Figueroa, John Mariadason, Ari Melnick, John Greally, Amit Verma
Journal: Blood
Blood (2006) 108 (11): 4189.
https://doi.org/10.1182/blood.V108.11.4189.4189
Published: 2006